Showing 1–7 of 7 results
-
Comments & Opinion |
Vemurafenib
- Keith T. Flaherty is at Massachusetts General Hospital...
-
News & Views |
Moving treatments earlier to move further forwards
- Keith T. Flaherty, MD, is a professor...
-
Reviews |
Precision medicine for cancer with next-generation functional diagnostics
- Keith T. Flaherty is an associate professor of...
-
Comments & Opinion |
Which questions remain unanswered following the successful development of sorafenib in hepatocellular carcinoma?
- Keith T Flaherty is an Assistant Professor of...
-
Reviews |
Targeted agents and immunotherapies: optimizing outcomes in melanoma
- Keith T. Flaherty gained his medical degree in...
-
Reviews |
Considerations for the successful co-development of targeted cancer therapies and companion diagnostics
- Keith T. Flaherty is Director of the Henri...
-
Reviews |
From genes to drugs: targeted strategies for melanoma
- Keith T. Flaherty is Director of Experimental Therapeutics...